EUVIMEDEUVIMED entdecken
Vergleichsstudie

Acute hospitalizations after proton therapy versus intensity‐modulated radiotherapy for locally advanced non–small cell lung cancer in the durvalumab era

Michelle Iocolano iD, Nikhil Yegya-Raman, Cole Friedes, Xingmei Wang, Timothy Kegelman, Sang Ho Lee, Lian Duan, Bolin Li, William P Levin, Keith A Cengel, Andre Konski, Corey J Langer und 11 weitere

Cancer · 2024

DOI: 10.1002/cncr.35230 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer, 2024. Verfasst von Michelle Iocolano und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiotherapy, Intensity-Modulated, Lung Neoplasms, Hospitalization. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

It was hypothesized that use of proton beam therapy (PBT) in patients with locally advanced non–small cell lung cancer treated with concurrent chemoradiation and consolidative immune checkpoint inhibition is associated with fewer unplanned hospitalizations compared with intensity‐modulated radiotherapy (IMRT).

Methods

Patients with locally advanced non–small cell lung cancer treated between October 2017 and December 2021 with concurrent chemoradiation with either IMRT or PBT ± consolidative immune checkpoint inhibition were retrospectively identified. Logistic regression was used to assess the association of radiation therapy technique with 90‐day hospitalization and grade 3 (G3+) lymphopenia. Competing risk regression was used to compare G3+ pneumonitis, G3+ esophagitis, and G3+ cardiac events. Kaplan–Meier method was used for progression‐free survival and overall survival. Inverse probability treatment weighting was applied to adjust for differences in PBT and IMRT groups.

Results

Of 316 patients, 117 (37%) received PBT and 199 (63%) received IMRT. The PBT group was older ( p < .001) and had higher Charlson Comorbidity Index scores ( p = .02). The PBT group received a lower mean heart dose ( p < .0001), left anterior descending artery V15 Gy ( p = .001), mean lung dose ( p = .008), and effective dose to immune circulating cells ( p < .001). On inverse probability treatment weighting analysis, PBT was associated with fewer unplanned hospitalizations (adjusted odds ratio, 0.55; 95% CI, 0.38–0.81; p = .002) and less G3+ lymphopenia (adjusted odds ratio, 0.55; 95% CI, 0.37–0.81; p = .003). There was no difference in other G3+ toxicities, progression‐free survival, or overall survival.

Conclusions

PBT is associated with fewer unplanned hospitalizations, lower effective dose to immune circulating cells and less G3+ lymphopenia compared with IMRT. Minimizing dose to lymphocytes may be warranted, but prospective data are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungRadiotherapy, Intensity-ModulatedLung NeoplasmsHospitalizationProton TherapyChemoradiotherapyHumansFemaleMaleAgedMiddle AgedRetrospective StudiesImmune Checkpoint InhibitorsLymphopeniaAntibodies, Monoclonal

Stichwörter der Autor:innen

carcinomahospitalizationintensity‐modulatedlung neoplasmslymphopenianon‐small cell lungproton therapyradiotherapy

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonaldurvalumab

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Radiation Oncology, Delaware Radiation Oncology Associates, Christiana Care Health Systems, Newark, Delaware, USA.
  • Department of Radiation Oncology, Division of Physics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Michelle Iocolano, Charles B Simone

Zitieren

APA

Iocolano, M., Yegya-Raman, N., Friedes, C., Wang, X., Kegelman, T., Lee, S. H., Duan, L., Li, B., Levin, W. P., Cengel, K. A., Konski, A., Langer, C. J., Cohen, R. B., Sun, L., Aggarwal, C., Doucette, A., Xiao, Y., Kevin Teo, B. K., O'Reilly, S., …, & Feigenberg, S. J. (2024). Acute hospitalizations after proton therapy versus intensity‐modulated radiotherapy for locally advanced non–small cell lung cancer in the durvalumab era. Cancer. https://doi.org/10.1002/cncr.35230

Vancouver

Iocolano M, Yegya-Raman N, Friedes C, Wang X, Kegelman T, Lee SH, et al. Acute hospitalizations after proton therapy versus intensity‐modulated radiotherapy for locally advanced non–small cell lung cancer in the durvalumab era. Cancer. 2024. doi:10.1002/cncr.35230

BibTeX
@article{Iocolano2024,
  author = {Iocolano, Michelle and Yegya-Raman, Nikhil and Friedes, Cole and Wang, Xingmei and Kegelman, Timothy and Lee, Sang Ho and Duan, Lian and Li, Bolin and Levin, William P and Cengel, Keith A and Konski, Andre and Langer, Corey J and Cohen, Roger B and Sun, Lova and Aggarwal, Charu and Doucette, Abigail and Xiao, Ying and Kevin Teo, Boon-Keng and O'Reilly, Shannon and Zou, Wei and Bradley, Jeffrey D and Simone, Charles B and Feigenberg, Steven J},
  title = {Acute hospitalizations after proton therapy versus intensity‐modulated radiotherapy for locally advanced non–small cell lung cancer in the durvalumab era},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35230}
}
Kostenlos starten →